Beam Therapeutics
BEAM
217 hedge funds and large institutions have $1.84B invested in Beam Therapeutics in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 84 increasing their positions, 65 reducing their positions, and 55 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 65
6.22% more ownership
Funds ownership: 101.55% → 107.77% (+6.2%)
7% less capital invested
Capital invested by funds: $1.99B → $1.84B (-$142M)
9% less funds holding
Funds holding: 238 → 217 (-21)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
35% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 55
62% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $37.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.5M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$14.2M |
| 4 |
Goldman Sachs
New York
|
+$10.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$35.4M |
| 2 |
Janus Henderson Group
London,
|
-$29.8M |
| 3 |
DM
Deerfield Management
New York
|
-$17.1M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.2M |
BEAM Hedge Fund Activity: Q2 2025 in Review
217 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2025, worth a combined $1.84B — down 7.1% from $1.99B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of BEAM and 36 opened new positions — a net loss of 19 holders — while 65 trimmed existing stakes and 84 added.
The largest buyer was Fidelity Investments, adding an estimated $87.8M. The largest seller was Temasek Holdings, exiting entirely with an estimated $35.4M sold.
- 217 institutional investors held Beam Therapeutics (BEAM) as of Q2 2025, down from 238 in Q1 2025.
- Funds reported $1.84B of Beam Therapeutics stock for Q2 2025, down 7.1% quarter-over-quarter.
- 36 funds opened new Beam Therapeutics positions in Q2 2025 and 55 closed out, a net change of -19 holders.
- The largest Beam Therapeutics buyer in Q2 2025 was Fidelity Investments, an estimated $87.8M added.
- The largest Beam Therapeutics seller in Q2 2025 was Temasek Holdings, an estimated $35.4M sold.
Based on aggregated 13F filings for Q2 2025.